Is Phibro Animal Health Corporation (PAHC) overvalued? · P/E 13, rev $1.52B
Phibro Animal Health Corporation (PAHC) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether Phibro Animal Health Corporation (PAHC) looks expensive on cached numbers — not a short thesis.
Latest reported PAHC revenue for 2026-06-30 was $1.52B. Net income was $99.7M. Revenue was up 17.1% from 2025-06-30 to 2026-06-30. PAHC currently screens at market cap $1.25B and trailing P/E 13.2.
PAHC currently screens at market cap $1.25B and trailing P/E 13.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PAHC 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PAHC stock page for the full model, not this heading.
Not investment advice.